Kaplan-Meier plots for OS of patients with recurrent and/or metastatic HNSCC comparing the predictive groups of survival benefit, good and poor, determined by the MS profile, when treated with EGFRIs as previously described (24). A, a cohort of patients treated with gefitinib (n = 55); B, a cohort of patients treated with erlotinib and bevacizumab (n = 32); C, a cohort of patients treated with cetuximab (n = 21); and D, a cohort of patients treated with docetaxel-containing palliative chemotherapy as a control (n = 34).